- Home
- URGN vs GFR Comparison
URGN vs GFR Comparison
Compare URGN & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- GFR
- Stock Information
- Founded
- URGN 2004
- GFR 2018
- Country
- URGN United States
- GFR Canada
- Employees
- URGN N/A
- GFR N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- GFR
- Sector
- URGN Health Care
- GFR
- Exchange
- URGN Nasdaq
- GFR Nasdaq
- Market Cap
- URGN 465.9M
- GFR 485.6M
- IPO Year
- URGN 2017
- GFR N/A
- Fundamental
- Price
- URGN $10.27
- GFR $6.92
- Analyst Decision
- URGN Strong Buy
- GFR Buy
- Analyst Count
- URGN 5
- GFR 1
- Target Price
- URGN $44.50
- GFR $10.50
- AVG Volume (30 Days)
- URGN 487.3K
- GFR 87.3K
- Earning Date
- URGN 03-13-2025
- GFR 02-14-2025
- Dividend Yield
- URGN N/A
- GFR N/A
- EPS Growth
- URGN N/A
- GFR N/A
- EPS
- URGN N/A
- GFR 0.40
- Revenue
- URGN $89,363,000.00
- GFR $551,353,492.00
- Revenue This Year
- URGN $13.39
- GFR $35.03
- Revenue Next Year
- URGN $45.06
- GFR $37.50
- P/E Ratio
- URGN N/A
- GFR $17.18
- Revenue Growth
- URGN 15.64
- GFR 11.20
- 52 Week Low
- URGN $9.78
- GFR $4.68
- 52 Week High
- URGN $20.70
- GFR $8.16
- Technical
- Relative Strength Index (RSI)
- URGN 39.53
- GFR 46.57
- Support Level
- URGN $10.12
- GFR $6.93
- Resistance Level
- URGN $10.96
- GFR $7.34
- Average True Range (ATR)
- URGN 0.57
- GFR 0.22
- MACD
- URGN -0.01
- GFR 0.01
- Stochastic Oscillator
- URGN 24.75
- GFR 14.81
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.